Pathology Research topic(s) - Universitäts KrebsCentrum Dresden ...

Pathology
Research topic(s):
1. Genotype-phenotype correlations in GI- and urogenital cancer
2. Proteases and protease receptors in tumor biology
Group leader(s):
Prof. Dr. med. Gustavo B. Baretton
Institute of Pathology
Medical Faculty Carl Gustav Carus
Technische Universität Dresden
Fetscherstraße 74
01309 Dresden
Ph.: +49-351-458 3000
Fax: +49-351-458 4328
E-mail: Gustavo.Baretton@uniklinikum-dresden.de
http://euroquant.med.tu-dresden.de/patholog/
Education:
1978-1984 Medical School, LMU Munich
1984 Approbation and Promotion
Training:
1986-1991 Residency Institute of Pathology, Medical University Lübeck
1991-2000 Fellowship and Faculty at the Institute of Pathology, LMU Munich
1995 Habilitation
Clinical Experience:
Surgical pathology: GI pathology, GU pathology, Hematology, Neuropathology.
Professional Appointments:
1999 C3-Professorship, LMU Munich
Since 01.10.2000 C4-Professorship for Pathology and Director of the Institute of
Pathology, TU Dresden
Since 2004 Speaker of the Project Group “GI-Pathology” of the German Society of
Pathology
Since 2007 Director UCC Tumor- and Normal Tissue Bank Since 1998
Reviewer of various Pathology Journals. Member of the Editorial Board
“Pathology Research & Practice” and “Urologia Internationalis”.
Publications: More than 180 scientific publications in peer reviewed journals
Funding: Extrabudgetary funding by DFG, industry, Deutsche Krebshilfe, Sander-
Stiftung
Journals: Member of the Editorial Board “Pathology Research & Practice” and “Urologia
Internationalis”. Reviewer for various pathology journals.
Societies: Executive Board Member of the German Society of Pathology (DGP), Member
of IAP, AACR, DGVS, DGE-BV (Board Member), DKG.
Group members:
Scientists:
Daniela E. Aust, Katrin Friedrich, Christiane Jakob, Matthias Kotzsch, Matthias Meinhardt,
Michael H. Muders, Marieta Toma, Kathrin Wieczorek
Internal collaborators:
Stephan Miehlke, Jan Stöhlmacher, Department of Internal Medicine I
Hans Konrad Schackert, Department of Surgical Research
Christian Pilarsky, Robert Grützmann, Department of Surgery
Manfred Wirth, Susanne Füssel, Department of Urology
Stand: 30.03.2011

Rolf Jessberger, Institut of Physiological Chemistry
Georg Breier, Institute of Pathology
External collaborators:
A. Tannapfel, Pathology Leipzig/Bochum
H. Becker, Surgery, Göttingen
German HNPCC-Consortium
D.J. Tindall, Mayo Clinic, Rochester, USA
K. Datta, University of Nebraska Medical Center, Omaha, USA
M. Schmitt and V. Magdolen, Gynecology, TU Munich
John Foekens, Erasmus Medical Center, Rotterdam, Netherlands
Participation in collaborative research projects (local, national, international):
German HNPCC-Consortium
EORTC GI-group, AOP/AIO translational research
List of ten most important publications 2005-2011:
1. Thiele S, Rauner M, Goettsch C, Rachner TD, Benad P, Fuessel S, Erdmann K,
Hamann C, Baretton GB, Wirth MP, Jakob F, Hofbauer LC. (2011) Expression profile of
WNT molecules in prostate cancer and its regulation by aminobisphosphonates. J Cell
Biochem. Epub ahead of print.
2. Toma MI, Weber T, Meinhardt M, Zastrow S, Grimm MO, Füssel S, Wirth MP, Baretton
GB. (2011) Expression of the Forkhead transcription factor FOXP1 is associated with
tumor grade and Ki67 expression in clear cell renal cell carcinoma. Cancer Invest.
29(2):123-9.
3. Kotzsch M, Bernt K, Friedrich K, Luther E, Albrecht S, Gatzweiler A, Magdolen V,
Baretton G, Zietz C, Luther T. (2010) Prognostic relevance of tumour cell-associated
uPAR expression in invasive ductal breast carcinoma. Histopathology. 57(3):461-71.
4. Eke I, Koch U, Hehlgans S, Sandfort V, Stanchi F, Zips D, Baumann M, Shevchenko A,
Pilarsky C, Haase M, Baretton GB, Calleja V, Larijani B, Fässler R, Cordes N.(2010).
PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha.
J Clin Invest. 120(7):2516-27.
5. Muders MH, Vohra PK, Dutta SK, Wang E, Ikeda Y, Wang L, Udugamasooriya DG,
Memic A, Rupasinghe CN, Baretton GB, Aust DE, Langer S, Datta K, Simons M, Spaller
MR, Mukhopadhyay D (2009).,Targeting GIPC/synectin in pancreatic cancer inhibits
tumor growth.Clin Cancer Res., 15(12):4095-103
6. Toma MI, Grosser M, Herr A, Aust DE, Meye A, Höfling C, Füssel S, Wuttig D, Wirth MP,
Baretton GB. (2008) Loss of heterozygosity and copy number abnormality in clear cell
renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide
polymorphism mapping array. Neoplasia. 10, 634-42.
7. Labelle M, Schnittler HJ, Aust DE, Friedrich K, Baretton G, Vestweber D, Breier G.
(2008) Vascular endothelial cadherin promotes breast cancer progression via
transforming growth factor beta signaling. Cancer Res. 68, 1388-97.
8. Friedrich K, Weber T, Scheithauer J, Meyer WD, Haroske G, Kunze KD, Baretton G.
(2008). Chromosomal genotype in breast cancer progression: Comparison of primary
andsecondary manifestations. Cell Oncol. 30, 39-50.
9. Jakob, C., Liersch, T., Meyer, W., Kulle, B., Baretton, G. B., Hausler, P., Schwabe, W.,
Hausler, P., Becker, H., and Aust, D. E. (2006). Prognostic value of histological tumor
regression, thymidylate synthase, thymidine phosphorylas, and dihydropyrimidine
dehydrogenase in rectal cancer UICC stage II/III after neoadjuvant chemotherapy. Am J
Surg Pathol 30, 1169-1168
10. Liersch, T., Langer, C., Ghadimi, M., Kulle, B., Aust, D.E., Baretton, G.B., Schwabe, W.,
Häusler, P., Becker, H., and Jakob, C. (2006). Lymph node status and TS-Gene
expression are prognostic markers in rectal cancer UICC stage II/III patiens after
neoadjuvant 5-FU-based chemoradiotherapy. J Clin Oncol 24, 4062-4067
Stand: 30.03.2011